Related Experiment Video
Updated: Nov 5, 2025

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology
Published on: May 31, 2024
Bisphosphonates Related Ocular Side Effects: A Case Series and Review of Literature
Omer Gendelman1,2, Liana Tripto-Shkolnik2,3, Iris Vered2,3
1Rheumatology Unit, Sheba Medical Center, Tel Hashomer, Israel.
Objective:
To describe the clinical features of patients with bisphosphonate related ocular side effects (BROSE).
Methods:
The medical records of all patients with BROSE between January 2009 and December 2019 were reviewed.
Results:
Nine cases with BROSE were identified. All subjects were female. Median age at diagnosis was of 69 years. The leading indication for bisphosphonate treatment was osteoporosis (n=7), Paget's disease of bone (n=1) and breast cancer (n=1). Six (66.67%) patients presented with uveitis, one (11%) episcleritis and two (22%) with orbital inflammation. Five events (55.5%) occurred within 10 days of initiating the bisphosphonate and the rest (44.44%) developed within 2 weeks to 3 years later. Four (44.44%) patients had concurrent thyroid disease. An association was found between underlying thyroid disease or autoimmunity.
Conclusion:
BROSE is an uncommon complication of bisphosphonate therapy occurring more frequently in patients with an autoimmune predisposition.
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment
Glaucoma: Overview
Osteoclasts in Bone Remodeling
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

